We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+27.07%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$39.1B
AUM Growth
+$5.57B
(+17%)
Cap. Flow
-$1.33B
Cap. Flow
% of AUM
-3.4%
Top 10 Holdings %
Top 10 Hldgs %
25.2%
Holding
834
New
111
Increased
262
Reduced
309
Closed
110
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$2.28B |
| 2 |
Otis Worldwide
OTIS
|
+$193M |
| 3 |
Burlington
BURL
|
+$191M |
| 4 |
AbbVie
ABBV
|
+$178M |
| 5 |
Wayfair
W
|
+$144M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$1.66B |
| 2 |
Lockheed Martin
LMT
|
+$339M |
| 3 |
Johnson & Johnson
JNJ
|
+$262M |
| 4 |
Pfizer
PFE
|
+$167M |
| 5 |
Target
TGT
|
+$141M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.52% |
| 2 | Healthcare | 19.78% |
| 3 | Consumer Discretionary | 13.09% |
| 4 | Financials | 11.33% |
| 5 | Industrials | 8.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
Xenon Pharmaceuticals
XENE
$6.22B
| $25.4M | 0.07% |
2,025,000
| – | – |
|
327
Archer Daniels Midland
ADM
$37.4B
| $25.1M | 0.06% |
629,492
+3,100
| +0.5% | +$116K |
|
328
Corpay
CPAY
$25.8B
| $25.1M | 0.06% |
99,808
+40,400
| +68% | +$9.59M |
|
329
Dollar Tree
DLTR
$24.7B
| $25M | 0.06% |
270,059
-797,832
| -75% | -$66.5M |
|
330
Welltower
WELL
$171B
| $25M | 0.06% |
482,506
+17,200
| +4% | +$845K |
|
331
Jazz Pharmaceuticals
JAZZ
$16.4B
| $24.8M | 0.06% |
+225,000
| New | +$24.9M |
|
|
XEC
332
DELISTED
CIMAREX ENERGY CO
XEC
| $24.2M | 0.06% |
880,655
-485,000
| -36% | -$12M |
|
333
ChargePoint
CHPT
$150M
| $24.1M | 0.06% |
120,000
| – | – |
|
|
DISH
334
DELISTED
DISH Network Corp.
DISH
| $24.1M | 0.06% |
697,267
-97,892
| -12% | -$2.72M |
|
335
Paychex
PAYX
$42.1B
| $24M | 0.06% |
317,046
+154,900
| +96% | +$10.7M |
|
336
VeriSign
VRSN
$26.5B
| $24M | 0.06% |
115,840
-2,000
| -2% | -$415K |
|
337
Equity Residential
EQR
$25.4B
| $23.9M | 0.06% |
406,233
+159,217
| +64% | +$9.86M |
|
338
Adient
ADNT
$1.61B
| $23.8M | 0.06% |
1,451,052
+201,052
| +16% | +$3.06M |
|
339
Western Alliance Bancorporation
WAL
$9.05B
| $23.8M | 0.06% |
628,834
+33,834
| +6% | +$1.18M |
|
340
FirstEnergy
FE
$27.7B
| $23.7M | 0.06% |
612,053
-611,339
| -50% | -$25.3M |
|
341
Alexandria Real Estate Equities
ARE
$8.73B
| $23.7M | 0.06% |
145,800
+8,200
| +6% | +$1.25M |
|
342
Equifax
EFX
$20.8B
| $23.6M | 0.06% |
137,500
+91,600
| +200% | +$13.6M |
|
343
DTE Energy
DTE
$29.1B
| $23.6M | 0.06% |
257,443
-2,232
| -0.9% | -$198K |
|
|
LPRO
344
DELISTED
Open Lending Corp
LPRO
| $23.4M | 0.06% |
1,552,874
+447,874
| +41% | +$5.08M |
|
|
PRSP
345
DELISTED
Perspecta Inc. Common Stock
PRSP
| $23.4M | 0.06% |
1,009,006
+988,806
| +4,895% | +$21.6M |
|
346
Hilton Worldwide
HLT
$73B
| $23.4M | 0.06% |
+319,100
| New | +$23.7M |
|
347
TransDigm Group
TDG
$70.2B
| $23.4M | 0.06% |
52,948
+22,246
| +72% | +$8.42M |
|
348
Realty Income
O
$58.5B
| $23.4M | 0.06% |
405,679
+3,509
| +0.9% | +$187K |
|
349
Ametek
AME
$58.4B
| $23.3M | 0.06% |
260,715
-632,196
| -71% | -$53M |
|
350
Northrop Grumman
NOC
$79.2B
| $23.1M | 0.06% |
+75,226
| New | +$24.7M |
|
Similar funds
Adage Capital Partners's Q2 2020 Portfolio in Review
As of Q2 2020, Adage Capital Partners held 834 positions worth $39.1B, up 17% from $33.5B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Adage Capital Partners withdrew a net $1.33B in Q2 2020, closing 110 positions and reducing 309 holdings. Its most notable exit was Allergan plc, an estimated $1.66B position sold in full.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 19% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Adage Capital Partners opened a new position in Royalty Pharma worth $2.23B.
- Adage Capital Partners's largest Q2 2020 buy was Royalty Pharma: 46,015,330 shares worth $2.23B.
- Adage Capital Partners added most to Burlington in Q2 2020, an estimated $191M increase.
- Adage Capital Partners's biggest Q2 2020 reduction was Lockheed Martin, cutting an estimated $339M.
- Adage Capital Partners fully exited Allergan plc in Q2 2020, selling an estimated $1.66B.
- Adage Capital Partners's ten largest holdings make up 25% of its $39.1B portfolio in Q2 2020.
- Adage Capital Partners opened 111 new positions and closed 110 in Q2 2020.
- Adage Capital Partners's portfolio value rose 17% quarter-over-quarter to $39.1B.
Based on Adage Capital Partners's 13F filing for Q2 2020, filed 14 Aug 2020.